Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492258 | 1.00 | GRIN2A (0.53) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 | |
| SCHEMBL1492160 | 0.88 | CYP2D6 (0.64) | GRIN2AGRIN1GRIN2BLMNAMEN1 | |
| SCHEMBL3130514 | 0.88 | TDP1 (0.55) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 | |
| SCHEMBL1492084 | 0.86 | GPBAR1 (0.70) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL1492108 | 0.86 | GPBAR1 (0.70) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL19506280 | 0.86 | GRIN2A (0.70) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 | |
| SCHEMBL1358415 | 0.86 | GRIN2A (0.59) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 | |
| SCHEMBL19506485 | 0.86 | GRIN2A (0.70) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 | |
| SCHEMBL1492107 | 0.85 | OSBP (0.52) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 | |
| SCHEMBL6064406 | 0.84 | GPBAR1 (0.53) | GRIN2AGRIN1GRIN2BGPBAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660720-B2 | Targeted oligonucleotide conjugates | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20030130220-A1 | Targeted oligonucleotide conjugates | IONIS PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6525031-B2 | Complexes carry primary moieties, chiefly therapeutic, to target cells; feature cell surface receptor ligands to provide specificity; ligands are preferably bound to primary moieties through polyfunctional manifold compounds. | ISIS PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
| US-20020058639-A1 | Targeted oligonucleotide conjugates | ISIS PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6300319-B1 | COMPLEX WITH MODULATION OF CELLS SURFACE RECEPTOR LIGANDS | ISIS PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
| WO-1999065925-A1 | TARGETED OLIGONUCLEOTIDE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | GRIN2A 4738/4885GRIN1 4305/4885GRIN2B 4655/4885 |
| US-20030130220-A1 | Targeted oligonucleotide conjugates | CD47, CD44, FOLR1 | GRIN2A 2667/4885GRIN1 3209/4885GRIN2B 3190/4885 |
| US-20020058639-A1 | Targeted oligonucleotide conjugates | CD47, CD44, FOLR1 | GRIN2A 2667/4885GRIN1 3209/4885GRIN2B 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.